AAPL338.40-2.67 (-0.78%) ▼|ABBV266.28+1.94 (+0.73%) ▲|ABT100.98-0.31 (-0.31%) ▼|ACN174.47-1.64 (-0.93%) ▼|ADBE231.01-4.46 (-1.89%) ▼|AMAT486.76+1.76 (+0.36%) ▲|AMD607.87-22.76 (-3.61%) ▼|AMGN418.13+3.52 (+0.85%) ▲|AMT168.00-1.03 (-0.61%) ▼|AMZN246.15-3.52 (-1.41%) ▼|AVGO349.57-3.24 (-0.92%) ▼|AXP306.33-2.56 (-0.83%) ▼|BA184.39-13.68 (-6.91%) ▼|BAC55.47-1.23 (-2.17%) ▼|BKNG163.87-0.08 (-0.05%) ▼|BLK1,071.25-15.06 (-1.39%) ▼|BMY63.88+1.02 (+1.62%) ▲|BNY148.44-1.71 (-1.14%) ▼|BRK-B503.09-2.39 (-0.47%) ▼|C131.31-2.97 (-2.21%) ▼|CAT819.95-1.63 (-0.20%) ▼|CL86.52+0.46 (+0.53%) ▲|CMCSA21.79-0.12 (-0.55%) ▼|COF196.46-3.74 (-1.87%) ▼|COP126.04-1.26 (-0.99%) ▼|COST922.92+0.16 (+0.02%) ▲|CRM227.27-6.75 (-2.88%) ▼|CSCO106.74+0.04 (+0.04%) ▲|CVS87.85-1.28 (-1.44%) ▼|CVX206.37+1.92 (+0.94%) ▲|DE689.59-0.87 (-0.13%) ▼|DHR227.33+2.84 (+1.27%) ▲|DIS105.59-0.56 (-0.53%) ▼|DUK113.41+0.06 (+0.05%) ▲|EMR159.39+1.16 (+0.73%) ▲|FDX289.65+3.80 (+1.33%) ▲|GD334.16-2.56 (-0.76%) ▼|GE318.24-8.85 (-2.71%) ▼|GEV949.77-7.86 (-0.82%) ▼|GILD152.21+1.28 (+0.85%) ▲|GM80.64-1.99 (-2.41%) ▼|GOOG339.16-1.92 (-0.56%) ▼|GOOGL342.75-1.17 (-0.34%) ▼|GS916.28-19.17 (-2.05%) ▼|HD289.89-3.31 (-1.13%) ▼|HON211.52-1.03 (-0.48%) ▼|IBM220.67-4.84 (-2.15%) ▼|INTC116.03-6.97 (-5.67%) ▼|INTU269.40-6.39 (-2.32%) ▼|ISRG414.79+9.61 (+2.37%) ▲|JNJ271.95+0.73 (+0.27%) ▲|JPM336.59-6.47 (-1.89%) ▼|KO87.18-0.63 (-0.72%) ▼|LIN472.04+2.15 (+0.46%) ▲|LLY1,184.78+1.32 (+0.11%) ▲|LMT518.10-1.46 (-0.28%) ▼|LOW187.66-1.62 (-0.86%) ▼|LRCX314.47-0.74 (-0.23%) ▼|MA568.26+0.61 (+0.11%) ▲|MCD233.60-2.90 (-1.23%) ▼|MDLZ60.18-0.07 (-0.12%) ▼|MDT89.50+0.86 (+0.97%) ▲|META715.62-36.04 (-4.79%) ▼|MMM169.48-0.07 (-0.04%) ▼|MO69.13+0.31 (+0.45%) ▲|MRK148.69-0.09 (-0.06%) ▼|MS193.64-2.67 (-1.36%) ▼|MSFT509.22-6.95 (-1.35%) ▼|MU1,053.98-28.30 (-2.61%) ▼|NEE75.49-0.59 (-0.78%) ▼|NFLX69.23-1.92 (-2.69%) ▼|NKE36.39+0.64 (+1.79%) ▲|NOW131.45-4.17 (-3.07%) ▼|NVDA228.86+3.79 (+1.68%) ▲|ORCL132.60-4.50 (-3.28%) ▼|PEP128.50-0.13 (-0.10%) ▼|PFE28.72+0.05 (+0.17%) ▲|PG149.03+2.80 (+1.91%) ▲|PLTR187.48-2.19 (-1.15%) ▼|PM193.76+3.28 (+1.72%) ▲|QCOM187.48-14.49 (-7.17%) ▼|RTX187.66-1.74 (-0.92%) ▼|SBUX95.27+0.41 (+0.43%) ▲|SCHW98.30-0.73 (-0.74%) ▼|SO82.35-0.53 (-0.64%) ▼|SPG204.53-0.29 (-0.14%) ▼|T24.90-0.48 (-1.89%) ▼|TMO678.60+3.60 (+0.53%) ▲|TMUS166.45+1.02 (+0.62%) ▲|TSLA357.45-14.66 (-3.94%) ▼|TXN278.31+0.24 (+0.09%) ▲|UBER68.16-1.46 (-2.10%) ▼|UNH377.83+1.24 (+0.33%) ▲|UNP274.10+0.31 (+0.11%) ▲|UPS94.25+0.29 (+0.31%) ▲|USB58.78-0.55 (-0.93%) ▼|V367.74+0.36 (+0.10%) ▲|VZ46.68-0.40 (-0.85%) ▼|WFC80.81-2.16 (-2.60%) ▼|WMT108.73+0.75 (+0.69%) ▲|XOM162.52+1.93 (+1.20%) ▲|AAPL338.40-2.67 (-0.78%) ▼|ABBV266.28+1.94 (+0.73%) ▲|ABT100.98-0.31 (-0.31%) ▼|ACN174.47-1.64 (-0.93%) ▼|ADBE231.01-4.46 (-1.89%) ▼|AMAT486.76+1.76 (+0.36%) ▲|AMD607.87-22.76 (-3.61%) ▼|AMGN418.13+3.52 (+0.85%) ▲|AMT168.00-1.03 (-0.61%) ▼|AMZN246.15-3.52 (-1.41%) ▼|AVGO349.57-3.24 (-0.92%) ▼|AXP306.33-2.56 (-0.83%) ▼|BA184.39-13.68 (-6.91%) ▼|BAC55.47-1.23 (-2.17%) ▼|BKNG163.87-0.08 (-0.05%) ▼|BLK1,071.25-15.06 (-1.39%) ▼|BMY63.88+1.02 (+1.62%) ▲|BNY148.44-1.71 (-1.14%) ▼|BRK-B503.09-2.39 (-0.47%) ▼|C131.31-2.97 (-2.21%) ▼|CAT819.95-1.63 (-0.20%) ▼|CL86.52+0.46 (+0.53%) ▲|CMCSA21.79-0.12 (-0.55%) ▼|COF196.46-3.74 (-1.87%) ▼|COP126.04-1.26 (-0.99%) ▼|COST922.92+0.16 (+0.02%) ▲|CRM227.27-6.75 (-2.88%) ▼|CSCO106.74+0.04 (+0.04%) ▲|CVS87.85-1.28 (-1.44%) ▼|CVX206.37+1.92 (+0.94%) ▲|DE689.59-0.87 (-0.13%) ▼|DHR227.33+2.84 (+1.27%) ▲|DIS105.59-0.56 (-0.53%) ▼|DUK113.41+0.06 (+0.05%) ▲|EMR159.39+1.16 (+0.73%) ▲|FDX289.65+3.80 (+1.33%) ▲|GD334.16-2.56 (-0.76%) ▼|GE318.24-8.85 (-2.71%) ▼|GEV949.77-7.86 (-0.82%) ▼|GILD152.21+1.28 (+0.85%) ▲|GM80.64-1.99 (-2.41%) ▼|GOOG339.16-1.92 (-0.56%) ▼|GOOGL342.75-1.17 (-0.34%) ▼|GS916.28-19.17 (-2.05%) ▼|HD289.89-3.31 (-1.13%) ▼|HON211.52-1.03 (-0.48%) ▼|IBM220.67-4.84 (-2.15%) ▼|INTC116.03-6.97 (-5.67%) ▼|INTU269.40-6.39 (-2.32%) ▼|ISRG414.79+9.61 (+2.37%) ▲|JNJ271.95+0.73 (+0.27%) ▲|JPM336.59-6.47 (-1.89%) ▼|KO87.18-0.63 (-0.72%) ▼|LIN472.04+2.15 (+0.46%) ▲|LLY1,184.78+1.32 (+0.11%) ▲|LMT518.10-1.46 (-0.28%) ▼|LOW187.66-1.62 (-0.86%) ▼|LRCX314.47-0.74 (-0.23%) ▼|MA568.26+0.61 (+0.11%) ▲|MCD233.60-2.90 (-1.23%) ▼|MDLZ60.18-0.07 (-0.12%) ▼|MDT89.50+0.86 (+0.97%) ▲|META715.62-36.04 (-4.79%) ▼|MMM169.48-0.07 (-0.04%) ▼|MO69.13+0.31 (+0.45%) ▲|MRK148.69-0.09 (-0.06%) ▼|MS193.64-2.67 (-1.36%) ▼|MSFT509.22-6.95 (-1.35%) ▼|MU1,053.98-28.30 (-2.61%) ▼|NEE75.49-0.59 (-0.78%) ▼|NFLX69.23-1.92 (-2.69%) ▼|NKE36.39+0.64 (+1.79%) ▲|NOW131.45-4.17 (-3.07%) ▼|NVDA228.86+3.79 (+1.68%) ▲|ORCL132.60-4.50 (-3.28%) ▼|PEP128.50-0.13 (-0.10%) ▼|PFE28.72+0.05 (+0.17%) ▲|PG149.03+2.80 (+1.91%) ▲|PLTR187.48-2.19 (-1.15%) ▼|PM193.76+3.28 (+1.72%) ▲|QCOM187.48-14.49 (-7.17%) ▼|RTX187.66-1.74 (-0.92%) ▼|SBUX95.27+0.41 (+0.43%) ▲|SCHW98.30-0.73 (-0.74%) ▼|SO82.35-0.53 (-0.64%) ▼|SPG204.53-0.29 (-0.14%) ▼|T24.90-0.48 (-1.89%) ▼|TMO678.60+3.60 (+0.53%) ▲|TMUS166.45+1.02 (+0.62%) ▲|TSLA357.45-14.66 (-3.94%) ▼|TXN278.31+0.24 (+0.09%) ▲|UBER68.16-1.46 (-2.10%) ▼|UNH377.83+1.24 (+0.33%) ▲|UNP274.10+0.31 (+0.11%) ▲|UPS94.25+0.29 (+0.31%) ▲|USB58.78-0.55 (-0.93%) ▼|V367.74+0.36 (+0.10%) ▲|VZ46.68-0.40 (-0.85%) ▼|WFC80.81-2.16 (-2.60%) ▼|WMT108.73+0.75 (+0.69%) ▲|XOM162.52+1.93 (+1.20%) ▲|
16.1 C
New York
Tuesday, September 29, 2026

Tag: source

SK Telecom and NVIDIA Build AI Infrastructure to Power Korea’s AI Innovation

Korea’s Leading Telco to Add NVIDIA-Powered AI Cloud Capacity Built on NVIDIA DSX AI Factory Architecture to Accelerate AI Startups, Robotics and Industrial Physical AI
Korea’s Leading Telco to Add NVIDIA-Powered AI Cloud Capacity Built on NVIDIA DSX AI Factory Architecture to Accelerate AI Startups, Robotics and Industrial Physical AI

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Phreesia, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PHR

NEW YORK, June 07, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Phreesia, Inc. (NYSE: PHR) between May 8, 2025 and March 30, 2026, inclusive (the “Class Period”), of the important July 13, 2026 lead plaintiff deadline.

He Predicted Gold at $5,000. Now He Says This $2 Stock Could Be Even Bigger.

A former CIA and Pentagon advisor says Trump is weeks away from unlocking the largest untapped mineral deposit in the United States
A former CIA and Pentagon advisor says Trump is weeks away from unlocking the largest untapped mineral deposit in the United States

Canadian Employers Invited to Create 10,000 New Opportunities Through National Inclusive Hiring Campaign

Enabled Talent launches One Company. One Talent, inviting Canadian employers to create one inclusive opportunity and build a stronger workforce.

GoHealth, Inc. to strengthen its position ahead of AEP 2026 through Restructuring Process supported by key stakeholders

Initiates voluntary prepackaged Chapter 11 process to implement Restructuring Transactions that have the support of 100% of its lenders, over 60% of the holders of GoHealth, Inc. Class A Common Stock, and over 99% of the holders of GoHealth Holdings, LLC interests.

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting...

Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),2 and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).4 Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.5,6

Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a first-in-class GIPR antagonist

Copenhagen, Denmark, 7 June 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today presented key Phase 1 and preclinical data for AT7687 at the 2026 Scientific Sessions of the American Diabetes Association®, held in New Orleans, Louisiana from June 5-8, 2026.

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Veritone, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – VERI

NEW YORK, June 07, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Veritone, Inc. (NASDAQ: VERI) between October 14, 2025 and April 14, 2026, inclusive (the “Class Period”), of the important July 20, 2026 lead plaintiff deadline.

Bronstein, Gewirtz & Grossman LLC Urges CommVault Systems, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for CommVault (CVLT) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 7/17/2026

Bronstein, Gewirtz & Grossman LLC Urges POET Technologies Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for POET Technologies Inc. urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 6/29/2026

Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Immutep (IMMP) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 7/6/2026

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsSource